PATENT
Attorney Docket No. 23853-A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Alan DRIZEN et al.

Serial No.: Not yet assigned

Filed: November 7, 2001

For: **TOPICAL DRUG PREPARATIONS**

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Before action in the above captioned application, and before calculation of the filing fee, please amend the application as follows:

IN THE SPECIFICATION

Before line 1, on page 1, please insert:

--This application is a divisional application of U.S. patent application Serial No. 09/288,233 filed April 8, 1999, which is a continuation of patent application Serial No. 08/796,578, filed February 6, 1997, which is a continuation-in-part application of U.S. Patent application Serial No. 08/536,750, filed September 29, 1995, the entire contents of which are hereby incorporated by reference in its entirety.--

Page 7, line 35, please change "105%" to --100%--.

Page 12, line 4, please change "ever" to --every--.

IN THE CLAIMS

Please cancel claims 1 to 44 without prejudice or disclaimer to the subject matter therein.

Please add the following claims:

--45. A composition for treating a dermatologic condition in an animal for a sustained period of time, which comprises:

a polymer matrix containing sodium hyaluronate and a nonionic polymer, said polymer being suspended in a liquid medium;

a therapeutically effective amount of a drug for treating said dermatologic condition disbursed within said polymer matrix;

wherein the molar ratio of the sodium hyaluronate to the nonionic polymer is 1:0.5 to 4, said sodium hyaluronate being present in amounts of about 2.0% to about 3.5% by weight of said composition; and

wherein said composition is capable of being topically applied to said animal to treat said dermatologic condition.--

--46. The composition of claim 45, wherein the drug for treating said dermatologic condition is selected from the group consisting of an amebicide, a broad spectrum antibiotic, a medium spectrum antibiotic, a fungal medication, a monobactam, a viral

agent, erythromycin, penicillin, cephalosporin, a derivative thereof and a combination thereof.--

--47. The composition of claim 45, wherein the molar ratio of the sodium hyaluronate to the nonionic polymer is 1:0.5 to 2.--

--48. The composition of claim 45, wherein the molar ratio of the sodium hyaluronate to the nonionic polymer is 1:0.7 to 2.5.--

--49. A composition for treating a dermatologic condition in an animal for a sustained period of time, which comprises:

a polymer matrix containing sodium hyaluronate and a nonionic polymer suspended in a liquid medium;

a therapeutically effective amount of a vitamin compound dispersed within said polymer matrix;

wherein the molar ratio of the sodium hyaluronate to the nonionic polymer is 1:0.5 to 4, said sodium hyaluronate being present in amounts of about 2.0% to about 3.5% by weight of said composition; and

wherein said composition is capable of being topically applied to said animal to treat the dermatologic condition.--

--50. The composition of claim 49, wherein said vitamin

compound is water-soluble.--

--51. The composition of claim 49, wherein said vitamin compound is selected from the group consisting of a B complex vitamin, vitamin C, folic acid, a derivative thereof and a combination thereof.--

--52. The composition of claim 51, wherein said B complex vitamin is pantothenic acid or a derivative thereof.--

--53. The composition of claim 52, wherein said derivative is sodium pantothenate.--

--54. A composition for treating dermatitis in an animal, which comprises:

a polymer matrix containing sodium hyaluronate and a nonionic polymer suspended in a liquid medium;

a therapeutically effective amount of a B complex vitamin compound or derivative thereof dispersed within said polymer matrix;

wherein said composition is capable of being topically applied to said animal to treat dermatitis.--

--55. The composition of claim 54, wherein said B complex vitamin is pantothenic acid or a derivative thereof.--

--56. The composition of claim 55, wherein said derivative is sodium pantothenate.--

--57. A method for treating a dermatologic condition in an animal, which comprises:

topically applying to said animal a therapeutically effective dose of a gelled composition for treating said dermatologic condition comprising a polymer matrix which is suspended in a liquid medium;

wherein the polymer matrix contains sodium hyaluronate in combination with a nonionic polymer.--

--58. The method of claim 57, wherein said condition is a pressure sore.--

--59. The method of claim 57, wherein said condition is dermatitis.--

--60. The method of claim 57, wherein said condition is atopic dermatitis.--

--61. A method for treating a dermatologic condition in an animal, which comprises:

topically applying to said animal a gelled composition comprising a therapeutically effective dose of a drug for treating the dermatologic condition uniformly distributed in a polymer matrix which is suspended in a liquid medium;

wherein the polymer matrix contains sodium hyaluronate in combination with a nonionic polymer.--

--62. The method of claim 61, wherein the drug for treating said dermatologic condition is selected from the group consisting of an amebicide, a broad spectrum antibiotic, a medium spectrum antibiotic, a fungal medication, a monobactam, a viral agent, erythromycin, penicillin, cephalosporin, a derivative thereof and a combination thereof.--

--63. The method of claim 61, wherein said dermatologic condition is a pressure sore.--

--64. The method of claim 61, wherein said dermatologic condition is dermatitis.--

--65. The method of claim 61, wherein said dermatologic

condition is atopic dermatitis.--

--66. A method for treating a dermatologic condition in an animal, which comprises:

topically applying to said animal a gelled composition comprising a therapeutically effective dose of a vitamin compound distributed in a polymer matrix which is suspended in a liquid medium;

wherein the polymer matrix contains sodium hyaluronate in combination with a nonionic polymer.--

--67. The method of claim 66, wherein said vitamin compound is selected from the group consisting of a B complex vitamin, vitamin C, folic acid, a derivative thereof and a combination thereof.--

--68. The method of claim 67, wherein said B complex vitamin is pantothenic acid or a derivative thereof.--

--69. The method of claim 68, wherein said derivative is sodium pantothenate.--

--70. The method of claim 66, wherein the condition is a

pressure sore.--

--71. The method of claim 66, wherein the condition is dermatitis.--

REMARKS

Upon entry of the above amendments, claims 45-71 are pending in the application. The specification has been amended, claims 1-44 have been canceled and claims 45-71 have been added to more clearly define applicants' inventive subject matter.

Basis for the newly added claims can be found on page 3, lines 21-25; page 4, line 2 to page 5 line 2; page 5, lines 6-25; page 8, lines 10-14; page 10, line 19 to page 11, line 13; page 17, lines 24-28; page 18, lines 23-24; and pages 19-21, Examples I and II. Therefore, applicants submit that the amendments do not introduce any new matter within the meaning of 35 U.S.C. §132. Accordingly, entry of the amendments is respectfully requested.

CONCLUSION

In view of the foregoing amendments and remarks, favorable action with early allowance of all pending claims is earnestly solicited.

The Examiner is welcome to telephone the undersigned attorney with any questions or comments.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date: November 7, 2011

Gary M. Nath
Reg. No. 26,965

NATH & ASSOCIATES PLLC
1030 15th Street, N.W.
Sixth Floor
Washington, D.C. 20005
Tel: (202) 775-8383
Fax: (202) 775-8396

GMN/TRL/eyd